A Phase 2 Study to Evaluate the Safety and Efficacy of Telisotuzumab Adizutecan for the Treatment of Subjects With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification

This study is testing a new experimental medicine called telisotuzumab adizutecan to see if it can safely and effectively treat advanced solid tumors. It is specifically designed for patients whose cancer has a genetic change called 'MET amplification,' which helps doctors identify if this medication might be a good fit for your tumor type.

You may be eligible if you have advanced cancer that has not responded well to standard treatments and has been confirmed to have the MET genetic change. Participants need to be generally active and able to perform daily tasks, and any cancer that has spread to the brain must be stable.

Participants will receive the study medication through an IV infusion at a clinic. Throughout the study, you will have regular check-ups, including blood tests, imaging scans, and questionnaires to track how your body responds to the treatment and to monitor for any side effects.

The study is currently recruiting participants at several locations, including Beverly Hills, Duarte, and Los Angeles, California. The trial is planned to last for over five years to ensure thorough monitoring of the medication's effects.